About AM-Pharma

Felice Verduyn-van Weegen, is an Investment Manager at LSP. She joined the Company in 2015.

Felice serves on the Boards of Pharvaris (GER) and OxThera (SE) as an Observer  and was a driving force behind the investments of Arvelle Therapeutics (NL/CH), Orphazyme (DK), Eloxx Pharmaceuticals (USA/IS), Simplify Medical (USA) and G-Therapeutics (NL).

Prior to joining LSP, Felice was a consultant at McKinsey & Company with a primary focus on healthcare. Before McKinsey, she was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge, USA. Prior to that, she worked at the department of Biological Psychology at the VU University in Amsterdam, the Netherlands. Felice authored a number of scientific articles in prestigious journals.

Felice was awarded a Bachelor’s degree in Biological Psychology and a Master’s degree in Neuroscience from the VU University, Amsterdam. In addition, she was awarded an MBA from Columbia Business School, New York USA.

Raphaël Wisniewskiis a Partner and joined the Life Sciences Team of Andera Partners (formerly Edmond de Rothschild Investment Partners) in 2001.

Raphaël serves as a DIrector on the Board of ReViral, MedDay Pharmaceuticals, Artios Pharma, Dynacure, Grey Wolf, Axonics Modulation and as an observer on the Boards of Poxel and Enyo.

Previously, he worked in Healthcare Corporate Finance at Goldman Sachs starting at Salomon Smith Barney. He was also in the Finance Departments of Health in London and in the Department of General Healthcare in London, the private hospital group.

Raphaël is a graduate of the Ecole des Hautes Etudes Commerciales, Paris and holds a Master’s degree in Economics and Finance from the Institut d’Etudes Politiques (IEP), Paris.

Geert-Jan Mulder, is a Managing Partner at Forbion and co-founded the fund in 2006. He currently serves on the Board of several Forbion portfolio companies. In addition, Geert-Jan led the firm’s successful investment in bluebirdbio (NASDAQ: BLUE), which went public in 2013, where he supported the Company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA^®(dalfampridine) board panel to evaluate a new regulatory endpoint in Multiple Sclerosis; PanGenetics B.V. which sold to Abbott, where he led the Series B financing round; Transave, where he supported the Company’s clinical development for ARIKAYCE^®(liposomal amikacin for inhalation) partly as interim CMO, he also served on the Board of Directors till the merger with Insmed (NASDAQ:INSM) in 2010; and Exosome Diagnostics, the leading liquid biopsy company spun out of MGH, where he led the Series A and C, and in his role of director worked together with management to position the Company for its successful acquisition by Bio-Techne (NASDAQ:TECH) in 2018. In addition he is a co-author of several Forbion and Forbion portfolio related scientific publications.

Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Geert-Jan received his Medical Degree from the University of Utrecht (NL) and spent two years as a clinician in Obstetrics and Gynecology at the University Medical Center of Utrecht (UMC). He then joined Searle (now Pfizer) working in the field of Arthritis & Pain, involved in clinical development as well as in the European Advocacy Development for the pre-launch of Celebrex^®. After transitioning to Byk Gulden (now Takeda) he became Clinical Research Manager, where his department was responsible for the design and execution of numerous early and late stage clinical trials that formed the basis for two global product registrations, i.e. Daxas^®and Alvesco^®in the field of Respiratory Medicine (asthma and COPD). He was a member of the Global Medical Marketing group of their Respiratory Franchise and was involved in the line extension program for Pantozol^®.

Rémi is a Managing Partner of Kurma Partners.

Prior to that, he held positions at CDC Innovation from 2000 to 2003 and at AGF Private Equity (now Idinvest Partners) from 2003 to 2010, where he was in charge of developing the life sciences investment activity.

Remi serves on the Board of Dynacure (France), ImCheck Therapeutics (France), Orphazyme (Denmark – listed on the Copenhagen Stock Exchange), Oxthera (France) and Pharvaris (the Netherlands).

Remi has an MSc in molecular biology (Paris VI University) and an MSc in finance and innovation management (AgroPariTech).

Joël is Managing Partner and Co-founder of Ysios Capital.

Previously, he co-founded GLYCART Biotechnology AG in 2001 and was its CEO until the Company was successfully sold to F. Hoffmann La-Roche in 2005. GLYCART’s lead product, obinituzumab (anti-CD20 antibody), was approved by FDA in 2013 for B-CLL. Obinituzumab (Gazyva®) was the first drug ever approved under the Breakthrough Therapy Designation program. Joël is currently on the Boards of Aura Biosciences Inc, Sanifit Therapeutics S.A., Rainier Therapeutics Inc. and Chairman of Inbiomotion S.L. He has been Chairman of the Board of Cellerix (now Tigenix NYSE Euronext TIG) and Board Observer at Boston-based Biovex Inc. (now Amgen).

He has earned numerous awards, including the Wall Street Journal Europe Innovation Award in 2001. Joël holds a PhD in the fields of cell biology and immunotherapy from the Swiss Federal Institute of Technology (ETH) in Zürich.

Rita Jain, M.D., Former Senior Vice President and Chief Medical Officer, Akebia Therapeutics, joined our Supervisory Board since April 2020. She is also a member of the Board of Directors for Chemocentryx. Previously, Dr. Jain served as the Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc and had management roles at AbbVie, Inc and prior to the split of AbbVie from Abbott, at Abbott Laboratories. Most recently, as Vice President of Men’s and Women’s Health and Metabolic Development at AbbVie, Inc., and she held various positions including Divisional Vice President at Abbott Laboratories. Dr. Jain also led activities in pain, respiratory, cystic fibrosis development, arthritis, inflammation and pain. Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine.

Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.